由于能识别多种类型人类癌肿相关抗原的单克隆抗体的发展,定位于肿瘤的抗体可用于结合治疗物质的设想已日益引起人们的注意。此法可通过下述二方面来加强治疗剂的疗效: 其一是改进抗癌剂在肿瘤的局部定位,特别是在转移灶的定位;另一方面是减少毒性反应,它使细胞毒药物在抗癌治疗上受到很大限制。一般说,结合高毒的抗癌剂,如植物毒素或其A 链(免疫毒素)是理想的,后者只要几个分子内在化(Internalization)后即可杀灭靶细胞,这时要求媒介抗体对肿瘤靶细胞必需具有高度的特异性,而且在抗体-毒素结合物和 Due to the development of monoclonal antibodies that recognize multiple types of human cancer-associated antigens, the idea that tumor-targeting antibodies can be used to bind therapeutic substances has increasingly attracted attention. This method can enhance the therapeutic effect of the therapeutic agent through the following two aspects: Firstly, to improve the localization of the anticancer agent in the tumor, especially in the location of the metastases; on the other hand, to reduce the toxic reaction, which makes the cytotoxic drugs Anti-cancer treatment is very limited. In general, it is desirable to combine a highly toxic anticancer agent such as a phytotoxin or its A-chain (immunotoxin), which kills target cells only after internalization of several molecules. This requires vector antibodies. Highly specific for tumor target cells, and in antibody-toxin conjugates and